Project 442965
Safety of systemic treatment in older adults with psoriatic disease
Safety of systemic treatment in older adults with psoriatic disease
Project Information
| Study Type: | Unclear |
| Research Theme: | Clinical |
Institution & Funding
| Principal Investigator(s): | Drucker, Aaron M; Tadrous, Mina |
| Co-Investigator(s): | Eder, Lihi; Fralick, Michael P; Gomes, Tara; Rochon, Paula A; Sutradhar, Rinku |
| Institution: | Women's College Hospital (Toronto) |
| CIHR Institute: | Musculoskeletal Health and Arthritis |
| Program: | |
| Peer Review Committee: | Clinical Investigation - B: Arthritis, Bone, Skin and Cartilage |
| Competition Year: | 2020 |
| Term: | 1 yr 0 mth |
Abstract Summary
Psoriasis is a chronic skin condition that can decrease quality of life substantially. It is sometimes associated with psoriatic arthritis, a debilitating joint disease. Both of these conditions are common among adults over age 65, but older patients are often excluded from medication trials for these conditions. As a result, we know little about how safe or unsafe medications for psoriasis and psoriatic arthritis are in older patients. In general, older men and women have a higher risk for serious medication side effects. This makes it important to understand the safety of medications for psoriasis and psoriatic arthritis among patients 65 and older. We will use data from Ontario to investigate the safety of medications for psoriasis and psoriatic arthritis in older men and women. Specifically, we will study the risk of serious infections, heart and attacks and strokes, emergency department visits, hospitalizations and death. We will also study whether certain characteristics put some patients at higher risk than others so that individual patients can make informed decisions about their own treatment.
No special research characteristics identified
This project does not include any of the advanced research characteristics tracked in our database.